The WGO 2017 guidelines (36) also recommend tTG IgA screening in patients with ATD as first-line tests for both symptomatic and asymptomatic patients with anti-endomysial antibodies (EMA) tests as confirmation. This evidence concerns the gene CD79A and Jeune syndrome.